Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 14 de 14
Filtrer
2.
J Invasive Cardiol ; 35(10)2023 Oct.
Article de Anglais | MEDLINE | ID: mdl-37984324

RÉSUMÉ

BACKGROUND: Right heart catheterization (RHC) usually is performed via the femoral vein or the internal jugular vein. However, the antecubital fossa vein is a valid venous access, and it has become increasingly popular to perform right heart catheterization utilizing this access. METHODS: A retrospective, observational study was conducted to describe use of the antecubital fossa vein for right heart catheterization in adults and children with congenital heart disease (CHD). Patients who had undergone RHC via antecubital fossa vein at the authors' hospital between September 2019 and December 2022 were included. The outcomes studied were procedural failure and procedure-related adverse events. RESULTS: Fifty-two patients with CHD underwent right cardiac catheterization via an upper arm vein. The upper arm vein was unable to perform the RHC in only 2 patients (3.8%). Only 1 patient developed a minor adverse event. No irreversible and/or life-threating adverse events were detected. CONCLUSIONS: The upper arm veins are safe and effective to perform a RHC in children and adults with CHD. This approach demonstrates a high percentage of technical success, and few mild complications.


Sujet(s)
Cathétérisme veineux central , Cardiopathies congénitales , Humains , Adulte , Enfant , Bras , Études rétrospectives , Études de faisabilité , Cardiopathies congénitales/diagnostic , Cardiopathies congénitales/chirurgie , Cathétérisme cardiaque/effets indésirables , Veines jugulaires , Veine fémorale
3.
Eur Heart J Case Rep ; 7(5): ytad238, 2023 May.
Article de Anglais | MEDLINE | ID: mdl-37215519

RÉSUMÉ

Background: Clinical thromboembolism in Fontan patients is often a catastrophic event resulting in death and adverse long-term outcomes. The treatment of acute thromboembolic complications in these patients is very controversial. Case summary: We describe the use of rheolytic thrombectomy in a Fontan patient with life-threatening pulmonary embolism, employing a cerebral protection system to reduce the risk of stroke through the fenestration. Discussion: Rheolytic thrombectomy may be a successful alternative to systemic thrombolytic therapy and open surgical resection for the treatment of acute high-risk pulmonary embolism in the Fontan population. Embolic protection device to capture and remove thrombus/debris may be an innovative tool to reduce the risk of stroke through the fenestration while performing a percutaneous procedure in fenestrated Fontan patient.

5.
G Ital Cardiol (Rome) ; 23(10): 775-792, 2022 Oct.
Article de Italien | MEDLINE | ID: mdl-36169129

RÉSUMÉ

Cardiovascular diseases are still the main cause of death among women despite the improvements in treatment and prognosis achieved in the last 30 years of research. The determinant factors and causes have not been completely identified but the role of "gender" is now recognized. It is well known that women tend to develop cardiovascular disease at an older age than men, and have a high probability of manifesting atypical symptoms not often recognized. Other factors may also co-exist in women, which may favor the onset of specific cardiac diseases such as those with a sex-specific etiology (differential effects of estrogens, pregnancy pathologies, etc.) and those with a different gender expression of specific and prevalent risk factors, inflammatory and autoimmune diseases and cancer. Whether the gender differences observed in cardiovascular outcomes are influenced by real biological differences remains a matter of debate.This ANMCO position paper aims at providing the state of the research on this topic, with particular attention to the diagnostic aspects and to care organization.


Sujet(s)
Maladies cardiovasculaires , Maladies cardiovasculaires/diagnostic , Maladies cardiovasculaires/épidémiologie , Maladies cardiovasculaires/étiologie , Oestrogènes , Femelle , Humains , Mâle , Pronostic , Facteurs de risque , Facteurs sexuels
6.
Card Electrophysiol Clin ; 14(3): 501-515, 2022 09.
Article de Anglais | MEDLINE | ID: mdl-36153130

RÉSUMÉ

The macroreentrant atrial tachycardia is very frequent in the adults with congenital heart disease. The impact of the arrhythmias on this type of patients is related to several factors: the anatomy and physiopathology of the specific congenital heart disease (CHD), the sequelae of the corrective surgery or surgical palliation, the presence of residual lesions (shunt, regurgitation), and the age and the clinical status of the patient and the comorbidities. In turn, the mechanism of the MAT depends on the peculiar features of the conduction's system in the CHD and native and acquired (post-surgery) substrates.


Sujet(s)
Flutter auriculaire , Ablation par cathéter , Cardiopathies congénitales , Tachycardie supraventriculaire , Adulte , Humains
7.
Int J Cardiol ; 366: 20-24, 2022 11 01.
Article de Anglais | MEDLINE | ID: mdl-35842002

RÉSUMÉ

In the recent years, the pregnancy trend among women with Congenital Heart Disease (CHD) has increased; this has leaded to a growing demand for specialized care both in mother and in children. Although pregnancy is often well tolerated, maternal CHD may affect in some cases a maladaptive hemodynamic response carrying additional risks of cardiovascular events like arrhythmias, heart failure and, in rare cases, death. The impaired utero-placental perfusion due to maternal cardiac status may result in placental dysfunction, which may be associated with fetal growth restriction, preeclampsia, premature birth and perinatal morbidity. Systemic Right Ventricle (SRV) is one of the main conditions under which pregnancy is challenging. The sub-aortic position of morphological Right Ventricle (RV) is "physiologically" predisposed to fail at the adult age and may be potentially inadequate to support the hemodynamic stress of the pregnancy. Current literature about pregnancy in women with SRV consists of small retrospective series not providing conclusive evidence about the feasibility of a successful pregnancy outcomes. In addition, the long-term effects of pregnancy on SVR are not still adequately investigated and it remains unclear if maternal complications reported are due to pregnancy or to natural history of SVR. The aim of this paper is to offer a critical review of the knowledges at regard and to provide a practice update on the risk assessment and the pregnancy management in women with SRV in order to support the decision making and to optimize outcomes in these patients.


Sujet(s)
Cardiopathies congénitales , Transposition des gros vaisseaux , Adulte , Artères , Enfant , Femelle , Ventricules cardiaques , Humains , Placenta , Grossesse , Issue de la grossesse/épidémiologie , Études rétrospectives , Transposition des gros vaisseaux/complications , Transposition des gros vaisseaux/imagerie diagnostique , Transposition des gros vaisseaux/chirurgie
8.
Echocardiography ; 39(5): 724-731, 2022 05.
Article de Anglais | MEDLINE | ID: mdl-35466466

RÉSUMÉ

OBJECTIVES: This study aimed to identify clinical, hemodynamic, or echocardiographic predictive features of persistent duct-dependency of pulmonary circulation (PDDPC) after effective percutaneous relief of pulmonary atresia with the intact ventricular septum (PA-IVS) or critical pulmonary stenosis (CPS). METHODS: From 2010 to 2021, 55 neonates with PA-IVS or CPS underwent percutaneous right ventricle (RV) decompression at our Institution. After successfully relief of critical obstruction, 27 patients (group I) showed PDDPC, whereas RV was able to support the pulmonary circulation in the remaining 28 patients (group II). Clinical, hemodynamic, and echocardiographic features of these two groups were compared. RESULTS: No significant difference in clinical and hemodynamic data was found between the groups, although the group I had a lower oxygen saturation at hospital admission. However, tricuspid valve (TV) diameter <8.8 mm, TV z-score ←2.12, tricuspid/mitral valve annular ratio <.78, pulmonary valve diameter <6.7 mm, pulmonary valve z-score ←1.17, end-diastolic RV area <1.35 cm2 , end-systolic right atrium area >2.45 cm2 , percentage amount of interatrial right-to-left shunt >69.5%, moderate/severe tricuspid regurgitation, RV systolic pressure >42.5 mmHg, tricuspid E/E' ratio >6.6 showed each significant predictive value of PDDPC. These parameters were used to build a composite echocardiographic score (PDDPC-score), assigning one point each above the respective cut-off value. A score ≥4.00 showed high sensitivity (100%) and specificity (86%) in predicting PDDPC. CONCLUSION: Clinical and hemodynamic features fail to predict the short-term fate of the pulmonary circulation after successful treatment of PA-IVS/CPS. However, a simple, composite echocardiographic score is useful to predict PDDPC and could be crucial in the management of this frail subset of patients.


Sujet(s)
Cardiopathies congénitales , Atrésie pulmonaire , Sténose de la valve pulmonaire , Valve du tronc pulmonaire , Sténose pathologique , Échocardiographie , Cardiopathies congénitales/chirurgie , Humains , Nouveau-né , Atrésie pulmonaire/imagerie diagnostique , Atrésie pulmonaire/chirurgie , Sténose de la valve pulmonaire/imagerie diagnostique , Sténose de la valve pulmonaire/chirurgie , Résultat thérapeutique
9.
G Ital Cardiol (Rome) ; 22(9): 756-766, 2021 Sep.
Article de Italien | MEDLINE | ID: mdl-34463685

RÉSUMÉ

Regular physical activity is essential for physical health and mental wellbeing in children and teenagers. However, patients with congenital heart disease are often restricted from being physically active due to parental overprotection and lack of physical activity promotion or exercise prescription from their physicians. A comprehensive medical evaluation is crucial for the development of personalized exercise programs for these patients. The aim of this review is to provide physicians with a practical guide on how to promote physical activity and prescribe exercise for patients with congenital heart disease with or without surgical correction.


Sujet(s)
Cardiologie , Cardiopathies congénitales , Adolescent , Enfant , Exercice physique , Humains , Italie , Ordonnances
10.
Ann Thorac Surg ; 105(5): 1441-1446, 2018 05.
Article de Anglais | MEDLINE | ID: mdl-29410185

RÉSUMÉ

BACKGROUND: The adult congenital heart surgery (ACHS) score was derived from The Society of Thoracic Surgeons Congenital Heart Surgery Database. The score was validated with data for 1,603 operations and reached a good predictive power. We sought to evaluate its predictive power for 1,654 operations performed in two European centers. METHODS: Data of all consecutive patients aged 18 years or more who underwent surgery for congenital heart disease between 2004 and 2013 at center 1 (n = 830) and between 2005 and 2016 at center 2 (n = 824) were collected. Mortality was defined as hospital mortality or mortality within 30 days after surgery. The discriminatory power of the ACHS score was assessed using the area under the receiver-operating characteristics curve (c-index). RESULTS: During the examined 13-year period, 1,639 operations of 43 different procedural groups were eligible for scoring. The most frequent procedures were closure of atrial septal defect (n = 175, 10.7%), repair of partial anomalous pulmonary venous connection (n = 117, 7.1%), and aortic valve replacement (n = 112, 6.8%). Hospital mortality was 3.1%. The procedures with the highest mortality were heart transplantation (3 of 11, 27.3%), mitral valve replacement (9 of 39, 23.1%), and systemic venous stenosis repair (2 of 9, 22.2%). The c-index for the ACHS mortality score was 0.760 (0.750 in center 1 and 0.772 in center 2). CONCLUSIONS: The ACHS score reached similar, good predictive power in two different centers. The score is a useful tool to analyze surgical outcomes and to support individual decision making.


Sujet(s)
Procédures de chirurgie cardiaque/mortalité , Cardiopathies congénitales/mortalité , Cardiopathies congénitales/chirurgie , Complications postopératoires/épidémiologie , Adulte , Procédures de chirurgie cardiaque/effets indésirables , France , Allemagne , Mortalité hospitalière , Humains , Appréciation des risques , Sensibilité et spécificité , Taux de survie , Résultat thérapeutique
11.
Int J Cardiol ; 238: 105-109, 2017 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-28318654

RÉSUMÉ

AIMS: Given the different pathogenesis, use of drug eluting stent (DES) in patients with Spontaneous Coronary Artery Dissection SCAD may delay the healing of the dissected vessel. Aim of our study was to compare the safety and the efficacy of DES vs. bare metal stent (BMS) in a cohort of patients who underwent stenting for SCAD. METHODS AND RESULTS: Consecutive patients with SCAD between January 1995 and August 2014 were retrospectively identified in 12 centers and included. Major Adverse Cardiac Events (MACE) was the primary end point. A total of 238 SCAD patients were identified: of them 108 patients underwent PCI with DES or BMS. Overall 24 patients (22.2%) suffered an intra-procedural complication without any differences between the 2 groups. At median follow-up of 1201days (Inter Quartile Range 541-2760), incidence of the primary endpoint showed a trend towards less events in the DES-treated patients (38.7% vs. 25.9% p=0.14) mainly driven by the benefit of DES in terms of TVR (17.6% vs. 4%, p=0.08), mortality (16.8% vs. 9.3%, p=0.4), and MI rate (16% vs. 8.4%, p=0.33). STEMI at presentation (HR 6.4, CI 95% 1.29-31.9, p=0.02) but not kind of stent (HR 0.97, CI 95% 0.2-4.7, p=0.9) emerged as independently related to prognosis at multivariable analysis. CONCLUSIONS: In SCAD patients use of DES seems to be as safe as BMS with trend of better efficacy in the long term.


Sujet(s)
Anomalies congénitales des vaisseaux coronaires/imagerie diagnostique , Anomalies congénitales des vaisseaux coronaires/chirurgie , Endoprothèses à élution de substances/normes , Intervention coronarienne percutanée/normes , Maladies vasculaires/congénital , Adulte , Sujet âgé , Endoprothèses à élution de substances/effets indésirables , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/méthodes , Enregistrements , Études rétrospectives , Résultat thérapeutique , Maladies vasculaires/imagerie diagnostique , Maladies vasculaires/chirurgie
12.
G Ital Cardiol (Rome) ; 17(3): 225-33, 2016 Mar.
Article de Italien | MEDLINE | ID: mdl-27029881

RÉSUMÉ

BACKGROUND: Adults with congenital heart disease are a relatively new population that progressively increases in size and complexity. In Italy, there are no accurate data concerning the distribution of congenital defects and the long-term outcome relating to both congenital heart disease per se and comorbidities, due to the aging process. METHODS: The Piedmont Adult Congenital Heart Disease Registry has been designed to investigate these aspects and to support a high quality healthcare development for grown-up congenital heart patients. Within 2 years, 459 consecutive patients routinely followed in 10 divisions of cardiology in Piedmont were included in the project. Electronic dedicated software has supported data collection. RESULTS: Mean age of patients is 35 ± 16 years. Septal defects are the most common type of congenital heart disease (35.3%). At baseline evaluation, 71.7% of patients reported a previous surgical and/or percutaneous treatment and 6.3% an electrophysiological procedure. Freedom from intervention is 44%, 81% and 56% at the age of 18, 30 and 45 years, respectively. Patients who had a treatment during infancy show a better intervention-free survival (p=0.038) compared with patients treated during adulthood. Despite the majority of the population had an almost preserved functional status, 27.5% had ≥1 long-term sequelae (arrhythmias 27.5%; pulmonary hypertension 5.2%; neurological problems 4.1%; cyanosis 4.8%; liver dysfunction 2.4%; enteropathy 2.4%; lung disease 2.2%). During 2 years of follow-up, the estimated mortality rate is 0.88%. CONCLUSIONS: Adults with congenital heart disease are a heterogeneous population of relatively young patients with relevant clinical and social problems. The late sequelae related to both the underlying heart disease and the advancing age require continuous monitoring and lifelong specialized care.


Sujet(s)
Cardiologie , Cardiopathies congénitales/mortalité , Cardiopathies congénitales/chirurgie , Enregistrements , Adulte , Angioplastie par ballonnet/tendances , Procédures de chirurgie cardiaque/tendances , Cardiologie/tendances , Dossiers médicaux électroniques/tendances , Femelle , Études de suivi , Cardiopathies congénitales/thérapie , Malformations des cloisons cardiaques/mortalité , Malformations des cloisons cardiaques/chirurgie , Humains , Italie/épidémiologie , Mâle , Adulte d'âge moyen , Prévalence , Études prospectives , Réintervention/tendances , Études rétrospectives , Appréciation des risques , Facteurs de risque , Taux de survie/tendances
13.
J Invasive Cardiol ; 24(12): 685-8, 2012 Dec.
Article de Anglais | MEDLINE | ID: mdl-23220987

RÉSUMÉ

Endovascular aneurysm repair is becoming the treatment of choice for elderly patients bearing abdominal aortic aneurysms with particular anatomical characteristics. Endovascular grafts are usually oversized to achieve sealing and minimize graft migration, the likelihood of which is also reduced by fixation hooks and barbs in the newer generation grafts. Yet, upward migration of the prosthesis, potentially compromising flow to renal and splanchnic vessels, may still occur acutely and requires timely management. We describe a patient with abdominal aortic aneurysm in whom proximal migration of an endovascular graft occurred, leading to renal and mesenteric artery obstruction, which was successfully managed by means of capturing and repositioning the device with a "horse-riding" technique followed by balloon stabilization of the graft to reduce the risk of re-dislodgment during controlateral leg insertion.


Sujet(s)
Angioplastie par ballonnet , Anévrysme de l'aorte abdominale/thérapie , Procédures endovasculaires/méthodes , Artère fémorale , Greffe vasculaire/méthodes , Sujet âgé , Angiographie , Anévrysme de l'aorte abdominale/imagerie diagnostique , Procédures endovasculaires/instrumentation , Humains , Mâle , Occlusion vasculaire mésentérique/complications , Occlusion artérielle rénale/complications , Résultat thérapeutique , Greffe vasculaire/instrumentation
14.
G Ital Cardiol (Rome) ; 13(6): 401-6, 2012 Jun.
Article de Italien | MEDLINE | ID: mdl-22622118

RÉSUMÉ

Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in men and women worldwide. The apparent cardioprotective effects of endogenous estrogens seem to prevent CVD in premenopausal women. Following menopause and loss of hormonal effects, gender-based differences in CVD are reduced, with the CVD risk being higher in women who develop the metabolic syndrome. In postmenopausal women, many features of the metabolic syndrome emerge with estrogen deficiency. Estrogen deficiency occurring in the menopausal period is associated with 1) dyslipidemia (hypertriglyceridemia, reduced HDL, and increased small dense LDL particles); 2) insulin resistance; 3) hypertension; 4) increased central fat and reduction in lean body mass; and 5) increased hypercoagulability and pro-inflammatory state. In addition to traditional cardiovascular risk factors, also early menopause has a negative impact on females. Over the past years, different approaches were found to improve quality of life and cardiovascular health in menopausal women. Since the concept of hormone replacement therapy (HRT), large observational studies and randomized clinical trials have amassed a wealth of data about the effects of menopause and the safety and efficacy of using estrogen replacement therapies to treat menopause symptoms and menopause-related diseases. While there is no question that HRT effectively mitigates troublesome menopause symptoms, conflicting evidence about other effects of HRT has fueled controversy concerning its relative benefits and risks. Moreover, it seems that CVD protection mediated by replacement therapy is maximum when treatment is initiated in the absence of signs of atherosclerosis (typically in the premenopausal period), whereas it vanishes as atherosclerosis progresses (postmenopausal period). However, many questions remain unsolved regarding the effectiveness of hormonal compounds, doses, regimens, and route of administration. On the basis of these considerations, it is necessary in the near future to expand scientific knowledge and develop appropriate lifestyle modifications and therapeutic strategies for the treatment of either traditional cardiovascular risk factors or menopause-related metabolic changes.


Sujet(s)
Oestrogénothérapie substitutive , Ménopause , Ischémie myocardique/étiologie , Ischémie myocardique/prévention et contrôle , Dyslipidémies/complications , Oestrogénothérapie substitutive/méthodes , Médecine factuelle , Femelle , Humains , Hypertension artérielle/complications , Insulinorésistance , Syndrome métabolique X/complications , Post-ménopause , Qualité de vie , Essais contrôlés randomisés comme sujet , Appréciation des risques , Facteurs de risque
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...